Abstract
Current treatment for HCV infections consists of approved direct acting antivirals (DAAs), viz. the protease inhibitors (boceprevir, telaprevir, and simeprevir), NS5B polymerase inhibitors (sofosbuvir) and NS5A inhibitor (ledipasvir) in combination with pegylated interferon α and ribavirin). These treatments have made a great improvement in the treatment of chronic HCV infections in recent years, but their adverse side effects, emergence of resistant mutants, high cost, and increased pill burden have limited their clinical use. Recently, with the increasing knowledge in understanding the HCV life cycle, more targets have been recognized. NS5A protein plays a critical role in assembly of infectious HCV particles and offering potential for HCV therapies. Therefore, discovery and development of novel DAAs targeting NS5A with novel mechanisms of action, are of great necessity to improve the quality of existing HCV treatments. In the present review, we discuss recent advances with NS5A inhibitors with potent anti-HCV activity, and the potential for the development of HCV NS5A inhibitors to combat HCV infections.
Keywords: Antivirals, drug design, HCV, hepatitis, inhibitors, NS5A.
Current Medicinal Chemistry
Title:The Changing Face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A
Volume: 22 Issue: 15
Author(s): Diwakar Rai, Liu Wang, Xuemei Jiang, Peng Zhan, Haiyong Jia, Erik De Clercq and Xinyong Liu
Affiliation:
Keywords: Antivirals, drug design, HCV, hepatitis, inhibitors, NS5A.
Abstract: Current treatment for HCV infections consists of approved direct acting antivirals (DAAs), viz. the protease inhibitors (boceprevir, telaprevir, and simeprevir), NS5B polymerase inhibitors (sofosbuvir) and NS5A inhibitor (ledipasvir) in combination with pegylated interferon α and ribavirin). These treatments have made a great improvement in the treatment of chronic HCV infections in recent years, but their adverse side effects, emergence of resistant mutants, high cost, and increased pill burden have limited their clinical use. Recently, with the increasing knowledge in understanding the HCV life cycle, more targets have been recognized. NS5A protein plays a critical role in assembly of infectious HCV particles and offering potential for HCV therapies. Therefore, discovery and development of novel DAAs targeting NS5A with novel mechanisms of action, are of great necessity to improve the quality of existing HCV treatments. In the present review, we discuss recent advances with NS5A inhibitors with potent anti-HCV activity, and the potential for the development of HCV NS5A inhibitors to combat HCV infections.
Export Options
About this article
Cite this article as:
Rai Diwakar, Wang Liu, Jiang Xuemei, Zhan Peng, Jia Haiyong, De Clercq Erik and Liu Xinyong, The Changing Face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A, Current Medicinal Chemistry 2015; 22 (15) . https://dx.doi.org/10.2174/0929867322666150209150920
DOI https://dx.doi.org/10.2174/0929867322666150209150920 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interleukin-7 Biology in HIV Disease and the Path to Immune Reconstitution
Current HIV Research Editorial (Thematic Issue: Measuring Myocyte Oxidative Stress and Targeting Cytokines to Evaluate Inflammatory Response and Cardiac Repair after Myocardial Infarction)
Current Vascular Pharmacology Assessing Drug Transport Across the Human Placental Barrier: From In Vivo and In Vitro Measurements to the Ex Vivo Perfusion Method and In silico Techniques
Current Pharmaceutical Biotechnology Subject Index to Volume 2
Current Vascular Pharmacology Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers
Current Alzheimer Research Zinc and Cell Signaling During Inflammation: Implications in Atherosclerosis
Current Nutrition & Food Science Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Novel Approaches to the Treatment of Obesity and Type 2 Diabetes Mellitus: Bioactive Leptin-Related Synthetic Peptide Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Can Environmentally Relevant Levels of Aluminium Promote the Onset and Progression of Neurodegenerative Diseases?
Current Inorganic Chemistry (Discontinued) Umbilical IgE and Advanced Glycation Products in Association with Allergies in Childhood
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Apoptosis and Atherosclerosis: The Role of Nitric Oxide
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Efficacy and Safety of Inhaled and Intranasal Corticosteroids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals Anti-inflammatory Effect of <i>Woodfordia fructicosa</i> Leaves Ethanolic Extract on Adjuvant and Carragenan Treated Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology Consideration of Cytokines as Therapeutics Agents or Targets
Current Pharmaceutical Design Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Analgesia in PACU: Indications, Monitoring, Complications
Current Drug Targets